Sodium-glucose co-transporter-2 know the patient and the drugs

被引：1
作者：
Lim, L. L. [1 ,2 ,3 ]
Chan, Juliana C. N. [1 ,3 ,4 ,5 ]
机构：
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Peoples R China
[2] Univ Malaya, Dept Med, Fac Med, Kuala Lumpur, Malaysia
[3] Asia Diabet Fdn, Hong Kong, Peoples R China
[4] Chinese Univ Hong Kong, Prince Wales Hosp, Hong Kong Inst Diabet & Obes, Hong Kong, Peoples R China
[5] Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China
来源：
HONG KONG MEDICAL JOURNAL | 2019年 / 25卷 / 04期
关键词：
CARDIOVASCULAR OUTCOMES; DIABETES-MELLITUS; INSULIN THERAPY; TYPE-2; EMPAGLIFLOZIN; AMPUTATIONS; INHIBITORS;
D O I：
10.12809/hkmj195089
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：268 / 270
页数：3
相关论文
共 24 条
[1]  
ASCHNER P, 2018, DIABETES S1, V67
[2]   Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors A Review of Spontaneous Postmarketing Cases [J].
Bersoff-Matcha, Susan J. ;
Chamberlain, Christine ;
Cao, Christian ;
Kortepeter, Cindy ;
Chong, William H. .
ANNALS OF INTERNAL MEDICINE, 2019, 170 (11) :764-+
[3]   Type 2 diabetes [J].
Chatterjee, Sudesna ;
Khunti, Kamlesh ;
Davies, Melanie J. .
LANCET, 2017, 389 (10085) :2239-2251
[4]  
Davies MJ, 2018, DIABETES CARE, V41, P2669, DOI [10.2337/dci18-0033, 10.1007/s00125-018-4729-5]
[5]   Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations [J].
Deerochanawong, Chaicharn ;
Chan, Siew P. ;
Matawaran, Bien J. ;
Sheu, Wayne H. -H. ;
Chan, Juliana ;
Man, Nguyen H. ;
Suastika, Ketut ;
Khoo, Chin M. ;
Yoon, Kun-Ho ;
Luk, Andrea ;
Mithal, Ambrish ;
Ji Linong .
DIABETES OBESITY & METABOLISM, 2019, 21 (11) :2354-2367
[6]   SGTL2 inhibitors and amputations in the US FDA Adverse Event Reporting System [J].
Fadini, Gian Paolo ;
Avogaro, Angelo .
LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (09) :680-+
[7]   Does insulin therapy have a hypertensive effect in type 2 diabetes? [J].
Genev, NM ;
Lau, IT ;
Willey, KA ;
Molyneaux, LH ;
Xu, ZR ;
Zilkens, RR ;
Wyndham, RN ;
Yue, DK .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 32 (01) :39-41
[8]   A contemporary update on Fournier's gangrene [J].
Hagedorn, Judith C. ;
WesselIs, Hunter .
NATURE REVIEWS UROLOGY, 2017, 14 (04) :205-214
[9]   Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial [J].
Inzucchi, Silvio E. ;
Iliev, Hristo ;
Pfarr, Egon ;
Zinman, Bernard .
DIABETES CARE, 2018, 41 (01) :E4-E5
[10]   Aspects of Multicomponent Integrated Care Promote Sustained Improvement in Surrogate Clinical Outcomes: A Systematic Review and Meta-analysis [J].
Lim, Lee Ling ;
Lau, Eric S. H. ;
Kong, Alice P. S. ;
Davies, Melanie J. ;
Levitt, Naomi S. ;
Eliasson, Bjorn ;
Aguilar-Salinas, Carlos A. ;
Ning, Guang ;
Seino, Yutaka ;
So, Wing Yee ;
McGill, Margaret ;
Ogle, Graham D. ;
Orchard, Trevor J. ;
Clarke, Philip ;
Holman, Rury R. ;
Gregg, Edward W. ;
Gagliardino, Juan Jose ;
Chan, Juliana C. N. .
DIABETES CARE, 2018, 41 (06) :1312-1320
123